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Abstract The first aim of this study was to assess the
diagnostic performance of presepsin (sCD14-ST) in post-
mortem serum from femoral blood compared to procalcito-
nin (PCT) to detect sepsis-related fatalities. The second aim
was to compare sCD14-ST levels found in postmortem
serum to the values in pericardial fluid to investigate the
usefulness of the latter as an alternative biological fluid.
Two study groups were formed, a sepsis-related fatalities
group and a control group. Radiology (unenhanced CT
scans and postmortem angiographies), autopsies, histology,
neuropathology, and toxicology as well as other postmortem
biochemistry investigations were performed in all cases.
Microbiological investigations on right cardiac blood were
carried out exclusively in septic cases. The results of this
study indicated that postmortem serum PCT and sCD14-ST
levels, individually considered, allowed septic cases to be
identified. Even though increases in both PCT and sCD14-
ST concentrations were observed in the control cases, co-
herent PCT and sCD14-ST results in cases with suspected
sepsis allowed the diagnosis to be confirmed. Conversely,
no relevant correlation was identified between postmortem
serum and pericardial fluid sCD14-ST levels in either the
septic or control groups.
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Introduction
Sepsis remains a major challenge in clinical practice with
considerable morbidity and mortality despite modern treat-
ments. Clinicians are in need of good diagnostic and prog-
nostic markers in order to identify infected patients who
would rapidly benefit from prompt, empirical antibiotic
therapy and other supportive treatment. Increased knowl-
edge on the pathophysiology and immunopathogenesis of
sepsis could therefore have the potential of generating new
diagnostic options and treatment modalities for this serious
condition [1].
In the realm of forensic pathology, notwithstanding ex-
tensive research and development in immunohistochemistry
and postmortem biochemical investigations, reliable diag-
noses of sepsis still remain difficult to formulate due to a
variety of reasons: unavailability of medical records before
autopsy is performed, uncertainty of macroscopic and mi-
croscopic findings as well as imprecise postmortem culture
results since accuracy may be influenced by postmortem
bacterial contamination [2].
In clinical practice, much effort has been directed to-
wards identifying biochemical parameters whose determi-
nation may provide useful information in the detection of
inflammatory states and confirm the existence of bacterial
infections. In general, C-reactive protein (CRP) is consid-
ered the biomarker of choice in detecting inflammations,
regardless of whether they are triggered by bacterial infec-
tions. Other biomarkers, such as procalcitonin (PCT) and
lipopolysaccharide-binding protein (LBP), seem to have a
pivotal role in the inflammatory host response to microbial
infections and are currently used in clinical practice as
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biological parameters to diagnose sepsis or severe bacterial
sepsis [3, 4].
In the forensic field, CRP and PCT can easily be mea-
sured in biological fluids obtained during autopsy (mainly
peripheral blood, cardiac blood, and postmortem serum) and
may be similarly used as in clinical practice [5, 6]. However,
their diagnostic performance in identifying sepsis-related
outcomes is incomplete. Despite its undoubted helpfulness
in identifying inflammatory states, increased CRP levels can
be observed in several non-infectious conditions [7–10].
Likewise, a number of non-infectious causes may induce
increased PCT levels including major surgery, severe trauma
without bacterial infections, exertion heat stroke, and major
burns [11–16].
Due to the complexity of the sepsis response, some
authors have postulated that a combination of several bio-
logical markers, rather than a single laboratory parameter,
could be more effective in order to obtain early and reliable
diagnosis of sepsis in living patients [17]. This same con-
sideration may be applied to the forensic field, where the
diagnosis of sepsis is even more difficult.
CD14, a cluster of differentiation (CD) marker protein
expressed on the surface of various cells including mono-
cytes, macrophages, neutrophils, and B cells is a multifunc-
tional cell surface glycoprotein, which exists either in a
glycosylphosphatidylinositol (GPI)-anchored membrane
form (mCD14) or in a circulating soluble form (sCD14)
[17–19]. Circulating plasma proteases activate a cleavage
of sCD14, generating a 13-kDa truncated N-terminal frag-
ment of 64 amino acid residues named sCD14 subtype
(sCD14-ST) or presepsin [17]. Yaegashi et al. [19] observed
that the concentration of sCD14-ST was increased in
patients with sepsis compared to healthy individuals and
patients with systemic inflammatory response syndrome
(SIRS). Analogous results were obtained by Endo et al. [4]
in a multicenter prospective study where sCD14-ST levels
in patients with systemic and localized bacterial infections
were significantly higher than those in patients with non-
bacterial infectious diseases.
In the study herein described, sCD14-ST, PCT, and CRP
levels were measured in postmortem serum from femoral
blood and pericardial fluid in a series of sepsis-related
fatalities and control individuals who underwent medicole-
gal investigations. The first objective of this study was to
assess the diagnostic performance of sCD14-ST compared
to PCT to detect sepsis-related fatalities. The second aim
was to compare postmortem serum sCD14-ST levels to
pericardial fluid concentrations to test the practicability of
using pericardial fluid as an alternative biological fluid.
Unenhanced CT scans, autopsy, histology, neuropathology,
and toxicology as well as other postmortem biochemical
analyses were also performed in all cases selected for this
study.
Material and methods
Subjects
Two study groups were formed, a sepsis-related fatalities
group and a control group. The sepsis-related fatalities
group consisted of 19 forensic autopsy cases. Nine of these
had been admitted to the intensive care unit of local hospi-
tals, where they died, and had documented clinical diagno-
ses of sepsis in vivo. The period of the septic condition was
between 24 h and 4 days.
No documented diagnoses of sepsis in vivo were noted in
the other ten cases, with no admittance to hospital prior to
death. Medical records were consistent with the existence of
infectious diseases. However, due to unclear circumstances
of death, autopsies were ordered by the public prosecutor
and the bodies transferred to the medicolegal center.
All cases included in the septic group (n019) underwent
complete autopsies between 5 and 62 hours after death (mean
postmortem period 19 h). The autopsies were always preceded
by unenhanced CT scans and, in selected cases, postmortem
angiographies. Histology, neuropathology, toxicology, and mi-
crobiological investigations on right cardiac blood were per-
formed in all cases of this group as well as biochemical analyses
on postmortem serum from femoral blood and vitreous humor.
The hypothesis of sepsis and multiple organ failure as the
cause of death was confirmed by postmortem investigations
in all the nine cases that had clinical diagnoses in vivo,
along with the exclusion of other causes of death.
The cause of death was attributed to multiple organ failure
in all ten cases that did not have clinical diagnoses of sepsis in
vivo based on the results of postmortem investigations. Un-
derlying septic states were postulated as the cause of multiple
organ failure. Alternative causes of death were excluded based
on autopsy and other forensic analyses. Descriptive character-
istics of the studied subjects, laboratory results, and main
postmortem investigation findings are reported in Table 1.
The control group consisted of 18 forensic autopsy cases.
None of the subjects included in this group had a docu-
mented, clinical diagnosis of sepsis in vivo and none had
been admitted to the hospital prior to death. As with the
group above, complete forensic autopsies were performed
between 8 and 65 h after death (mean 30 h), always preced-
ed by unenhanced CT scans and, in selected cases, by
postmortem angiographies. Histology, neuropathology, and
toxicology were performed in all cases, as well as biochem-
ical analyses on postmortem serum from femoral blood and
vitreous humor. Microbiology was not performed in any of
the cases of this group. Postmortem investigations failed to
reveal findings consistent with the existence of underlying
bacterial infections or septic states.
Causes of death were determined to be drug intoxication
(four cases), hanging (two cases), coronary thrombosis
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(three cases), ischemic heart disease (two cases), chronic
myocardial insufficiency (one case), carbon monoxide in-
toxication (one case), positional asphyxia (one case), and
hepatic insufficiency (one case). In one case, death occurred
in the context of generalized seizures. In two cases, the
causes of death remained undetermined even after all post-
mortem investigations had been performed. Both cases oc-
curred in women presenting chronic eating disorders.
Descriptive characteristics of the control group subjects,
laboratory results, main postmortem investigation findings
and causes of death are reported in Table 2.
Sample collection
Postmortem serum from femoral blood
Using a sterile needle and syringe, postmortem blood samples
were collected by aspiration through the femoral vein during
autopsy. All blood samples were centrifuged immediately
post-collection at 3,000×g for 15 min. After centrifugation,
the separated supernatant (postmortem serum) was collected,
stored in preservative-free tubes, and frozen at −20 °C until
analysis.
Right cardiac blood
The external side of the right atrium was sterilized by sear-
ing with a heated scalpel blade, and the cardiac blood was
aspirated using a syringe. Once collected, the blood was
stored in blood-culture bottles (aerobic and anaerobic) and
immediately incubated at 37 °C.
Pericardial fluid
Undiluted samples of pericardial fluid were collected
immediately post pericardium incision during autopsy.
Table 1 Results for the septic group (n019, 11 males and 8 females, mean age 49.5 years) with characteristics of the investigated subjects,
laboratory results (postmortem serum), and main postmortem investigation findings
Subject Postmortem
interval (h)
Age Gender Clinical
diagnosis
of sepsis
PCT CRP sCD14-ST Microbiology
findings
Medical records,
radiology, autopsy,
and histology findings
1 23 63 M Yes 20.28 172 5,280 m.b. Pneumoniae
2 25 46 F Not 23.37 270 4,910 m.b. Peritonitis
3 34 70 M Not 2.62 62 8,960 P. aeruginosa Necrotising myocarditis,
fibrinous pericarditis,
pneumonia
4 15 48 F Not 13.50 372 1,890 E. coli Pyelonephritis
5 14 49 M Not 0.06 76 2,280 m.b. Pneumonia, antibiotic
treatment
6 14 80 F Not 2.76 61 750 E. coli Pneumonia
7 5 57 F Not 155.70 229 4,420 m.b. Abdominal infection
8 62 63 F Not 13.62 306 2,810 m.b. Peritonitis
9 21 74 F Not 2.31 98 1,170 m.b. Alzheimer, broncho-aspiration,
pneumonia
10 5 2 months
old
M Yes 47.13 3 92 K. pneumoniae Pneumonia, percutaneous
gastrostomy tube
11 22 46 M Yes 3.77 58 1,750 E. coli Pneumonia
12 12 17 M Yes 16.58 25 1,760 K. pneumoniae Sickle cell disease,
lymphadenomegaly,
splenomegaly, pneumonia
13 10 66 M Yes 85.50 285 2,220 P. aeruginosa Pneumonia
14 11 32 M Yes 6.04 56 1,680 n.i. Multiple organ failure
15 15 78 M Yes 8.87 130 1,680 E. coli Pneumonia
16 18 48 F Yes 27.75 150 4,160 K. pneumoniae Pneumonia
17 23 41 F Yes 4.02 161 1,470 m.b. Pneumonia, antibiotic therapy
18 12 17 M Not 3.68 148 1,770 E. coli Pneumonia
19 27 45 M Not 47.34 272 1,310 E. coli Necrotising fasciitis
M male; F female; PCT procalcitonin (results are expressed in micrograms per milliliter); CRP C-reactive protein (results are expressed in
milligrams per liter); sCD14-ST soluble cluster of differentiation 14 subtype (results are expressed in picograms per milliliter); n.i. not clearly
identifiable pathogens; m.b. multiple bacteria
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All samples were immediately centrifuged at 3000×g
for 15 min. After centrifugation, the separated superna-
tant was collected, stored in preservative-free tubes and
frozen at −20 °C until analysis.
Laboratory assays
Determination of PCT concentrations
PCT was measured by commercially available immunoas-
says on the Roche Modular E170 analyzer (Roche Diagnos-
tic, Mannheim, Germany) using a postmortem serum from
femoral blood. Results were expressed in micrograms per
liter. The analytical sensitivity was 0.1 μg/l, according to
manufacturer information.
Determination of CRP concentrations
CRP was measured by the commercially available
immunoturbidometric assay on the Roche Modular P-
system (Roche Diagnostics, Mannheim, Germany) us-
ing postmortem serum from femoral blood. Results
were expressed in milligrams per liter. The analytical
sensitivity was 0.15 mg/l, according to manufacturer
information.
Determination of sCD14-ST concentrations
sCD14-STconcentrations were measured by a rapid, commer-
cially available chemiluminescent enzyme immunoassay
(CLEIA) based on a noncompetitive CLEIA combined with
Magtration® technology [20]. The method was optimized on
an automated immunoassay analyzer (PATHFAST™, Gepa
Diagnostics, Milan, Italy) [21]. During incubation of the sam-
ple with alkaline phosphatase-labeled anti sCD14-ST poly-
clonal and monoclonal antibodies coated with magnetic
particles, sample sCD14-ST presepsin binds to the antibodies
forming an immunocomplex with enzyme-labeled antibodies
and antibody-coated magnetic particles. After removing the
unbound substances via Magtration® technology, a chemilu-
minescent substrate is added. After a short incubation, the
luminescence intensity generated by the enzyme reaction,
which is proportional to the sCD14-ST concentration, is mea-
sured. The final result is calculated by means of a standard
calibration curve performed by using a standard calibrator
material containing recombinant sCD14-ST; the calibrator
value was assigned by amino acid analysis. Results are auto-
matically corrected by entering the corresponding hematocrit
value. Quality specifications of this CLEIA have been previ-
ously assessed, according to CLSI EP17-A [21, 22]. Intra-assay
imprecision, expressed as coefficient of variation (in percent-
age) ranges from 2.7 to 7.1 % with linearity of 94.7–104.6 %
Table 2 Results for the control
group (n018, 11 males and 7
females, mean age 45 years)
with characteristics of the inves-
tigated subjects, laboratory
results (postmortem serum),
main postmortem investigation
findings, and causes of death
M male; F female; PCT procal-
citonin (results are expressed in
micrograms per milliliter); CRP
C-reactive protein (results are
expressed in milligrams per li-
ter); sCD14-ST soluble cluster of
differentiation 14 subtype
(results are expressed in pico-
grams per milliliter)
Subject Postmortem
interval (h)
Gender Age PCT CRP sCD14-
ST
Radiology, autopsy, histology,
and toxicology findings
20 65 M 35 0.06 2 210 Coronary thrombosis
21 42 M 22 0.06 2 480 Toxic (heroin)
22 48 F 66 0.35 17 4,890 Hepatic insufficiency
23 12 M 57 0.06 2 890 Toxic (multiple drugs)
24 42 F 45 0.06 2 650 Coronary thrombosis
25 15 F 44 0.06 2 290 Hanging
26 24 M 45 0.06 2 510 Coronary thrombosis
27 33 F 46 0.06 2 410 Toxic (carbon monoxide)
28 18 F 58 0.06 2 180 Toxic (multiple drugs)
29 8 M 43 0.06 2 830 Chronic myocardial insufficiency
30 20 M 70 0.06 2 690 Ischemic heart disease
31 23 M 55 0.06 2 270 Ischemic heart disease
32 9 M 27 0.06 2 380 Hanging
33 18 F 33 0.06 2 1,460 Undetermined (eating disorder)
34 32 M 42 0.06 2 1,170 Epilepsy
35 51 M 46 5.21 52 1,170 Toxic (multiple drugs)
36 24 M 61 8.26 11 1,570 Positional asphyxia
37 48 F 31 25.48 85 1,840 Undetermined (eating disorder,
renal insufficiency)
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In our study, postmortem serum from femoral blood and
pericardial fluid were used as samples. Results were
expressed in picograms per milliliter. The analytical sensi-
tivity was 20 pg/ml, according to manufacturer information.
Other analyses
Other biochemical analyses were performed according to
laboratory standards and internal quality control protocols.
Ethical aspect
All cases collected for this study underwent medicolegal
autopsies as requested by the public prosecutor. Biochemi-
cal analyses, including PCT, CRP, and sCD14-ST measure-
ments, were performed as part of the medicolegal
investigations. No further ethical permission was required
to perform laboratory analyses.
Statistical analyses
Data were analyzed by using STATA statistical software pack-
age (STATA Corporation, College Station, TX, USA).
Receiver-operator characteristic curves, sensitivity, and speci-
ficity values were calculated to assess the performance of the
selected biomarkers as diagnostic markers for sepsis. The diag-
nostic accuracy of the studied markers was determined by the
area under the curves (AUC). According to laboratory refer-
ences in living people, PCT values were dichotomized into
“non-septic values” (concentrations lower than 2 μg/l) and
“septic values” (concentrations greater than 2 μg/l), and CRP
values into “normal values” (concentrations lower than 10 mg/
l) and “increased values” (concentrations greater than 10 mg/l).
A cutoff value of 600 pg/ml was chosen for sCD14-ST based
on the results of the clinical study of Endo et al. [4]. According
to these authors, this value yielded optimal sensitivity and
specificity for the diagnosis of bacterial infections in living
people. The relationship between sCD14-ST in postmortem
serum and sCD14-ST in pericardial fluid was explored: the
non-parametric measure of dependence between the two vari-
ables was expressed as Spearman’s rank correlation coefficient
or Spearman’s rho. The linear dependence between the two
variables was assessed by Pearson’s product–moment coeffi-
cient. R and Rho values ≥0.7 were considered to define a strong
correlation between variables, respectively; while R and Rho
ranging between 0.69 and 0.5 and 0.49 to 0.3 were considered
to define moderate and low correlation, respectively.
Results
Tables 1 and 2 summarize the main laboratory results (post-
mortem serum PCT, CRP, and sCD14-ST levels) and
autopsy findings in the sepsis cases and control individuals.
The bivariate fit of postmortem serum and pericardial fluid
sCD14-ST concentrations in the sepsis (Fig. 1a) and control
group (Fig. 1b) is reported in Fig. 1. Statistical results are
reported in Table 3.
Sepsis and multiple organ failure were confirmed to be
the causes of death according to postmortem investigations
in all the nine cases that had clinical diagnoses of sepsis in
vivo and the exclusion of other causes of death.
The cause of death was attributed to multiple organ
failure in the other ten cases that did not have clinical
diagnoses of sepsis in vivo based on the results of postmor-
tem investigations. Underlying septic states were postulated
as provoking multiple organ failures. Alternative causes of
death were excluded according to autopsy and further post-
mortem investigations.
Assuming that normal and pathological PCT and CRP
blood levels in living people show similar ranges as in
postmortem serum from femoral blood, only one individual
(case 5) among the sepsis-related fatalities presented a nor-
mal postmortem serum PCT value (0.06 μg/l), though with
an increased postmortem serum CRP concentration (76 mg/
l). The sCD14-ST value was also increased (2,280 pg/ml) in
this case. Blood cultures revealed the presence of multiple
Gram-positive and Gram-negative bacteria. Histology
revealed multiple foci of polynuclear neutrophils in both
lungs.
Furthermore, only one individual (case 10) among the
sepsis-related fatalities presented a normal postmortem se-
rum CRP value (3 mg/l), whereas postmortem serum PCT
concentration was significantly increased (47.13 mg/l). In-
terestingly, the sCD14-ST value (92 pg/ml) was the lowest
observed in either study group. This case, a 2-month-old
infant, represented the only CRP and sCD14-ST negative
case in the sepsis group.
Among septic cases, sCD14-ST concentrations ranged
from 92 to 8,960 pg/ml, with a mean value of 2,650 pg/
mg (median 4,420 pg/ml). In 18 cases out of 19, sCD14-ST
levels were higher than 600 pg/ml (cutoff value).
Increased levels of both PCTand sCD14-STwere observed
in 17 septic cases out of 19, of both PCT and CRP in 17 cases
out of 19, and of both CRP and sCD14-ST in 18 cases out of
19. Lastly, increased PCT, CRP, and sCD14-ST concentra-
tions were simultaneously observed in 17 cases out of 19.
In the 18 control individuals, postmortem investigations
failed to identify findings consistent with the existence of
underlying bacterial infections or septic states.
Again, assuming that normal and pathological PCT and
CRP blood levels in living people show similar ranges in
postmortem serum from femoral blood, three cases were
observed that revealed simultaneous increases in both PCT
and sCD14-ST levels (cases 35, 36, and 37). These cases
also showed higher CRP levels. PCT concentrations were
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lower than 2 μg/ml in 15 cases out of 18, and CRP levels
were normal in 14 out of 18.
sCD14-ST values ranged from 180 to 4,890 pg/ml, with a
mean value of 993 pg/mg (median 670 pg/ml). Concentra-
tions were greater than 600 pg/ml in ten cases out of 18.
Among them, sCD14-ST was the only increased parameter
in six cases (cases 23, 24, 29, 30, 33, 34).
As expected, postmortem serum PCT values were higher
in the sepsis group and differed between the two groups,
with only one false-negative case in the sepsis group (which
showed both increased CRP and sCD14-ST levels) and
three false-positives in the control group (which also
showed both increased CRP and sCD14-ST levels).
Similarly, postmortem serum CRP levels were higher in
the sepsis group and differed between the two groups, with
only one false-negative case in the sepsis group (which also
showed a normal sCD14 level) and four false-positives in
the control group (among these, three cases also showed
both increased PCT and sCD14-ST levels and one case
showed a significantly increased sCD14-ST value).
Using a cutoff value of 600 pg/ml, sCD14-ST deter-
mination in postmortem serum revealed one false-
negative case in the sepsis group and ten false-
positives in the control group (sensitivity 94.74 %,
specificity 44.44 %). PCT in postmortem serum showed
the same sensitivity as sCD14-ST (94.74 %), whereas
specificity (83.33 %) was better.
Using a cutoff value of 750 pg/mg, sensitivity and spec-
ificity were unchanged; whereas using a cutoff value of
1,200 pg/ml, sCD14-ST determination revealed three false-
negative cases in the sepsis group and four false-positives in
the control group, with a sensitivity of 84.21 % and a
specificity of 77.78 % (AUC 0.81).
The simultaneous determination of both PCT and sCD14-
ST (cutoff 600 pg/ml) showed satisfactory sensitivity and
specificity (89.47 and 83.33 %, respectively, AUC 0.91).
Using a cutoff value of 1,200 pg/ml, the sensitivity was
100 % and specificity, 72.22 % (AUC 0.92).
Lastly, the results of the data analysis showed that peri-
cardial fluid sCD14-ST levels were similar in both studied
groups, thereby suggesting that pericardial fluid sCD14-ST
determination cannot be considered an option should post-
mortem serum be unavailable.
Figure 1 shows the bivariate fit of postmortem serum and
pericardial fluid sCD14-ST concentrations in the sepsis
cases (Fig. 1a) and control individuals (Fig. 1b). No mono-
tonic correlation exists between the two variables (Spear-
man’s rho 0 −0.28 and −0.14 in the sepsis and control
groups, respectively, and p value >0.2 for both groups)
and no linear dependence between the two variables was
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Fig. 1 Bivariate fit of
postmortem serum and
pericardial fluid sCD14-ST
concentrations in the sepsis
cases (a) and control individu-
als (b)
Table 3 Sensitivity, specificity, and area under the curve for PCT, CRP, and sCD14-ST in postmortem serum and pericardial fluid
PCT S CRP S sCD14-ST S
(cutoff value 600
pg/ml)
sCD14-ST PF PCT and sCD14-ST
(cutoff value 600 pg/ml)
sCD14-ST S
(cutoff value
1,200 pg/ml)
PCT and sCD14-ST
(cutoff value 1,200
pg/ml)
Sensitivity 94.74 % 94.74 % 94.74 % 94.74 % 89.47 % 84.21 % 100 %
Specificity 83.33 % 77.78 % 44.44 % 0 83.33 % 77.78 % 72.22 %
AUC 0.89 0.96 0.84 0.54 0.91 0.81 0.92
False positive 3 4 10 18 3 4 5
False negative 1 1 1 0 2 3 0
S postmortem serum from femoral blood; PF pericardial fluid; PCT procalcitonin (results are expressed in micrograms per milliliter); CRP C-
reactive protein (results are expressed in milligrams per liter); sCD14-ST soluble cluster of differentiation 14 subtype (results are expressed in
picograms per milliliter); AUC area under the curve
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shown by Pearson’s product–moment coefficient in the sep-
sis group (r squared 0 0.03, correlation 0 −0.179, p value
0.46). Moderate linear dependence emerged in the control
group (r squared 0 0.83, correlation 0 0.62, p value 0.006).
Discussion
The primary aim of this study was to investigate the diag-
nostic performance of sCD14-ST in postmortem serum from
femoral blood in order to identify sepsis-related fatalities.
The usefulness of sCD14-ST was compared to that of PCT
which represents, at present, the laboratory parameter of
choice in the realm of forensic investigations to corroborate
the hypothesis of sepsis as the cause of death based on
clinical, anamnestic, macroscopic, and microscopic find-
ings. A cutoff value of 600 pg/ml was chosen based on the
results of the clinical study of Endo et al. [4] in living
people. We furthermore wished to test the usefulness of
pericardial fluid as an alternative biological fluid for
sCD14-ST determination.
Concerning the first objective of the study, the results of
our analyses indicated that postmortem serum PCT and
sCD14-ST levels, individually considered, allow septic
cases to be identified.
Even though simultaneous increases in both PCT and
sCD14-ST levels were observed in the control cases, most
of the septic cases were characterized by concomitant
increases in both markers, thus suggesting that their com-
bined determination can be a useful tool in confirming the
existence of septic states or sepsis-related fatalities.
Since sepsis is a major cause of mortality in intensive
care units, reliable diagnoses may have a major impact on
the clinical course, management, and outcome [7, 23] of
these cases. In clinical situations, biochemical markers that
could discriminate between non-infectious SIRS and sepsis
as well as between infections of bacterial or viral etiology
would be of great importance in making effective treatment
decisions [23, 24].
In the realm of forensic pathology, autopsy findings and
routine histology in cases of suspected fatal bacterial sepsis
are most often unspecific and unconvincing. The identifica-
tion of biochemical parameters that reliably add to the
postmortem diagnosis of sepsis is highly desirable for med-
icolegal purposes [25–30].
CD14 is a GPI-anchored protein constitutively expressed
by cells of myeloid origin. Aside from the membrane-bound
state (mCD14), CD14 is also found in a circulating soluble
form (sCD14). mCD14 has been shown to be a specific
receptor for lipopolysaccharide (LPS), a compound from
the outer cell wall of Gram-negative bacteria. LPS circulat-
ing in blood is carried by the LPS-binding protein (LBP), an
acute-phase protein, where the LPS–LBP complex may
subsequently interact with the cell surface receptor mCD14
and form a high affinity trimolecular complex LBP-LPS-
CD14. This complex mediates monocyte activation via Toll-
like receptors, thus inducing the release of a cascade of
proinflammatory cytokines [31–36]. Besides binding LPS,
CD14 may function as a receptor for peptidoglycan, the
major cell wall component of Gram-positive bacteria [17,
18].
A soluble form of CD14, that lacks the GPI anchor, can
be shed by activated monocytes from the plasma membrane
and circulate in relatively high concentrations in normal,
adult human serum, also binding bacterial structures [18,
34, 36]. Moreover, it can be suggested that sCD14 could be
an acute-phase protein since, apart from a protease-mediated
shedding form originating from leukocytes, a soluble form
is also produced by hepatocytes, representing the major
source of acute-phase proteins. However, though CD14 is
known to be synthesized in human hepatocytes, nothing is
known about the humoral mediators that regulate its pro-
duction [18].
Evidence has accumulated to show that sCD14 serves as
an acute-phase reactant parallel with CRP, a classical acute-
phase protein [36]. In a study of Bas et al. [18], sCD14
levels were elevated in various inflammatory arthropathies
(infection-mediated, crystal-induced, and immunologically
mediated) and correlated with those of CRP and IL-6.
Numerous clinical studies have reported significantly
elevated serum levels of sCD14 in inflammatory conditions
such as Kawasaki disease, atopic dermatitis, liver disease,
rheumatoid arthritis, systemic lupus erythematosus, and pri-
mary Sjögren syndrome. Correlations between sCD14 lev-
els and disease activity in systemic lupus erythematosus and
the severity of trauma in polytraumatized patients have also
been published [32, 37–45].
sCD14 plasma concentrations in adults and neonatal sep-
tic cases have been investigated in several studies and com-
pared by some authors with other biochemical markers
levels of inflammation and infection, mainly PCT, CRP,
interleukin-6, tumor necrosis factor-alpha, LPS, and LBP
[7, 23, 35, 36, 46–49]. The results of these studies showed
increased sCD14 values in newborns and adults with sepsis
as well as higher sCD14 levels in septic cases than in
healthy control individuals. Pavcnik-Arnol et al. [23] ob-
served that the diagnostic accuracy of sCD14 for sepsis was
markedly higher in neonates than in children and superior to
that of PCT, which suggested a distinct regulation of bio-
chemical mediators for inflammation and infection in neo-
nates and children. Berner et al. [35] observed significantly
elevated sCD14 and LBP levels in samples from septic
neonates when compared to samples from healthy control
neonates. Furthermore, the authors documented elevated
concentration of either sCD14 or LBP in 15 cases of infec-
tion caused by Gram-positive bacteria, which do not possess
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LPS as constituents of their cell wall. These findings sug-
gested that, apart from Gram-negative bacteria, Gram-
positive bacteria are also capable of inducing significant
sCD14 increases in vivo. Blanco et al. [48] documented
increased sCD14 values in Gram-positive bacteria septic
cases, though to a lesser extent than in Gram-negative
bacteria sepsis. Herrmann et al. [7] and Landmann et al.
[46, 47] observed higher sCD14 plasma concentrations in
septic cases than in healthy control individuals, with the
highest levels in patients with non-Gram-negative sepsis
[47]. Again, these findings suggested that, apart from LPS
of Gram-negative bacteria, sCD14 may also bind to cell wall
components of Gram-positive microorganisms or mycobac-
teria and that bacterial wall components other than LPS may
induce increases in sCD14 serum levels.
The truncated form of sCD14, renamed sCD14 subtype
(sCD14-ST) or presepsin, is a novel marker for the diagno-
sis of sepsis that has been shown to increase in blood in the
early stages of sepsis [50]. Yaegashi et al. [19] observed that
the levels of sCD14-ST in septic patients were significantly
higher than those in patients with SIRS or healthy control
subjects. Compared with PCT, sCD14-ST was induced at
earlier stages of sepsis, was present at higher concentrations
in plasma and was a more sensitive indicator of sepsis.
In a multicenter prospective study performed by Endo et
al. [4], the presepsin assay was as helpful for the diagnosis
of bacterial infections as PCT, with no significant differ-
ences in presepsin levels between Gram-positive and Gram-
negative bacterial infection groups. Despite a comparable
usefulness of presepsin to PCT for the diagnosis of bacterial
infections, the clinical specificity of sCD14-ST proved sig-
nificantly higher than that of PCT, with several false-
positive PCT patients displaying sCD14-ST levels less than
600 pg/ml. According to the authors, the presepsin cutoff
value of 600 pg/ml yielded optimal sensitivity and specific-
ity. Interestingly, sCD14-ST levels in two patients suffering
from chronic renal failure were markedly increased, sug-
gesting caution in interpreting presepsin levels above the
cutoff value in such patients.
The results of our analyses seem to confirm the findings
obtained by Yaegashi et al. [19] and Endo et al. [4], indicating
that cases of bacterial sepsis are characterized by increased
sCD14-ST levels in postmortem serum from femoral blood.
Indeed, only one individual (case 10, PCT 47.13) among
sepsis-related fatalities presented a sCD14-ST value lower
than 600 pg/ml along with a normal CRP concentration
(3 mg/l). This case was the only child of the studied septic
group. It is interesting to notice that Maeda et al. [51] had
already described normal postmortem serum CRP levels in
some infantile pneumonia cases. The authors ascribed this
result to an age-dependent limited inflammatory response.
However, Pavcnik-Arnol et al. [23] observed that the diag-
nostic accuracy of sCD14 for sepsis was higher in neonates
than in children and superior to that of PCTwhich suggested,
according to the authors, a distinct regulation of biochemical
mediators for inflammation and infection in neonates and
children. The results of Pavcnik-Arnol et al. [23] are based
on clinical observations obtained in a larger, more representa-
tive septic population and partly contradict those of our anal-
yses, which are based on a single infantile septic case.
Though further studies are required to confirm our find-
ings, the results of our investigations indicated a high diag-
nostic accuracy for PCT and sCD14-ST in detecting sepsis-
related fatalities in the postmortem period. Coherent PCT
and sCD14-ST results could thereby represent a promising
diagnostic tool in forensic pathology to corroborate the
existence of septic states.
We must highlight, however, the speculation that sCD14-
ST may partly continue to generate in the early postmortem
period since circulating plasma proteases activate the cleav-
age of sCD14 to produce CD14-ST. Henceforth, a sCD14-
ST cutoff value greater than 600 pg/ml might be more
realistic in forensic pathology.
According to this rationale, the results of data analysis
showed that sensitivity and specificity were unmodified
using a cutoff value of 750 pg/ml, whereas specificity was
significantly improved using a cutoff value of 1,200 pg/ml.
Our results also revealed that sCD14-ST increases coher-
ently with CRP levels in almost all cases. This observation
can be extended to both septic and control individuals, with
the only exceptions being cases 14 and 15 in the control
group. These findings would corroborate the function of
CD14/sCD14-ST as an acute-phase reactant, as already pos-
tulated by numerous clinical studies.
Lastly, no associations were identified between postmor-
tem serum and pericardial fluid sCD14-ST levels in either
the septic or control groups. This means that sCD14-ST
determination in pericardial fluid cannot be considered an
alternative to postmortem serum when postmortem bio-
chemistry could help in identifying the cause of death and
postmortem serum is not available during autopsy.
In conclusion, the results of our investigations indicate
that, as in the clinical field, sCD14-ST can be considered a
promising biological parameter for the diagnosis of sepsis in
forensic pathology routine.
Simultaneous assessments of PCT and sCD14-ST should
be performed on a case-by-case basis when contradictory
findings require further investigations, and measurements of
other biochemical markers may be helpful in order to reach
more definite conclusions.
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